Sugi Predict

Sugi Predict / Compounds / SCHEMBL10075112

SCHEMBL10075112

SCHEMBL10075112

O=C(COCOC(=O)Oc1ccccc1)Oc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.42
▸ PRSS1 P07477 1/20 0.41
▸ PRSS2 P07478 1/20 0.41
▸ PRSS3 P35030 1/20 0.41
▸ ALOX15 P16050 2/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ ELANE P08246 1/20 0.39
▸ HSD17B10 Q99714 3/20 0.38
▸ HTT P42858 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ ATM Q13315 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ PAM P19021 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10025073 0.83 MAPT (0.46) CYP19A1ALOX15ALDH1A1MEN1KMT2A
SCHEMBL11437247 0.83 CYP19A1 (0.52) CYP19A1PRSS1PRSS2PRSS3ALOX15
SCHEMBL15106968 0.81 ELANE (0.42) ALOX15ALDH1A1MEN1KMT2AELANE
SCHEMBL11595637 0.81 GAA (0.45) CYP19A1PRSS1PRSS2PRSS3ALOX15
SCHEMBL3438961 0.80 CYP19A1 (0.49) CYP19A1PRSS1PRSS2PRSS3ALOX15
SCHEMBL14707361 0.79 ELANE (0.46) CYP19A1PRSS1PRSS2PRSS3ALOX15
SCHEMBL3438962 0.78 CYP19A1 (0.47) CYP19A1PRSS1PRSS2PRSS3ALOX15
SCHEMBL14370917 0.78 ALOX15 (0.50) ALOX15ALDH1A1MEN1KMT2AMAPT
SCHEMBL10075111 0.78 ALOX15 (0.55) CYP19A1PRSS1PRSS2PRSS3ALOX15
SCHEMBL13415664 0.78 LMNA (0.46) ALDH1A1MEN1KMT2AHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160193179-A1 Treatment of Cardiovascular Risk in Diabetic Patients SAKARIASSEN KJELL STEINAR (IT) 2016-07-07 — — US disclosed
US-9260406-B2 Substituted 1,3-dioxanes useful as PPAR modulators EVOLVA SA (CH) 2016-02-16 — — US disclosed
US-20150158838-A1 Prodrugs of Substituted 1,3-Dioxanes and Their Uses EVOLVA SA (CH) 2015-06-11 — — US disclosed
US-8952053-B2 Prodrugs of substituted 1,3-dioxanes and their uses EVOLVA SA (CH) 2015-02-10 — — US disclosed
US-20130267561-A1 Substituted 1,3-Dioxanes Useful as PPAR Modulators EVOLVA SA (CH) 2013-10-10 — — US disclosed
US-20130253045-A1 Prodrugs of Substituted 1,3-Dioxanes and Their Uses EVOLVA SA (CH) 2013-09-26 — — US disclosed
US-8536196-B2 Substituted 1,3-dioxanes useful as PPAR modulators EVOLVA SA (CH) 2013-09-17 — — US disclosed
US-20130197030-A1 Substituted 1,3-Dioxanes and There Uses EVOLVA SA (CH) 2013-08-01 — — US disclosed
US-8486994-B2 Prodrugs of substituted 1,3-dioxanes and their uses EVOLVA SA (CH) 2013-07-16 — — US disclosed
US-20120252836-A1 1,3-Dioxanes and Their Uses EVOLVA SA (CH) 2012-10-04 — — US disclosed
US-20120142766-A1 SUBSTITUTED 1,3-DIOXANES AND THEIR USES EVOLVA SA (CH) 2012-06-07 — — US disclosed
US-20100273824-A1 SUBSTITUTED 1,3-DIOXANES AND THEIR USES EVOLVA SA (CH) 2010-10-28 — — US disclosed
US-20100168169-A1 SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS EVOLVA SA (CH) 2010-07-01 — — US disclosed
US-20100087517-A1 PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES EVOLVA SA (CH) 2010-04-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160193179-A1 Treatment of Cardiovascular Risk in Diabetic Patients P2RY12, P2RY13, P2RY6 CYP19A1 3114/4885PRSS1 1151/4885PRSS2 1634/4885
US-20100087517-A1 PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES TBXA2R, PPARG, PPARA CYP19A1 28/4885PRSS1 1498/4885PRSS2 1991/4885
US-20120142766-A1 SUBSTITUTED 1,3-DIOXANES AND THEIR USES TBXA2R, PPARG, PPARA CYP19A1 43/4885PRSS1 1692/4885PRSS2 2237/4885
US-20130197030-A1 Substituted 1,3-Dioxanes and There Uses TBXA2R, PPARG, PPARA CYP19A1 40/4885PRSS1 1558/4885PRSS2 1981/4885
US-20100273824-A1 SUBSTITUTED 1,3-DIOXANES AND THEIR USES TBXA2R, PPARG, PPARA CYP19A1 43/4885PRSS1 1692/4885PRSS2 2237/4885
US-20120252836-A1 1,3-Dioxanes and Their Uses TBXA2R, PPARG, PPARA CYP19A1 52/4885PRSS1 1562/4885PRSS2 2295/4885
US-20100168169-A1 SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS PPARD, PPARG, PPARA CYP19A1 275/4885PRSS1 1772/4885PRSS2 3294/4885
US-20130267561-A1 Substituted 1,3-Dioxanes Useful as PPAR Modulators PPARD, PPARG, PPARA CYP19A1 275/4885PRSS1 1772/4885PRSS2 3294/4885
US-20130253045-A1 Prodrugs of Substituted 1,3-Dioxanes and Their Uses TBXA2R, PPARG, PPARA CYP19A1 28/4885PRSS1 1498/4885PRSS2 1991/4885
US-20150158838-A1 Prodrugs of Substituted 1,3-Dioxanes and Their Uses TBXA2R, PPARG, PPARA CYP19A1 28/4885PRSS1 1498/4885PRSS2 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.